Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.55 - $6.53 $5.59 Million - $8.03 Million
-1,229,236 Reduced 30.35%
2,820,982 $17.5 Million
Q3 2023

Nov 14, 2023

BUY
$2.95 - $4.8 $273,394 - $444,844
92,676 Added 2.34%
4,050,218 $15.8 Million
Q2 2023

Aug 14, 2023

BUY
$1.98 - $4.33 $3.44 Million - $7.52 Million
1,736,712 Added 78.2%
3,957,542 $16.3 Million
Q4 2022

Feb 14, 2023

SELL
$2.44 - $5.42 $61,000 - $135,500
-25,000 Reduced 1.11%
2,220,830 $6.97 Million
Q3 2022

Nov 10, 2022

SELL
$4.95 - $6.6 $612,998 - $817,330
-123,838 Reduced 5.23%
2,245,830 $11.3 Million
Q2 2022

Aug 15, 2022

BUY
$4.12 - $7.51 $9.76 Million - $17.8 Million
2,369,668 New
2,369,668 $13.4 Million

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $5.73M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.